Comments
Shares of Jubilant Life Sciences surged 10.4 per cent in early trade to its highest since October 28. The company has obtained approval from US FDA for two key drugs.
These approvals will act as medium-term positive for the stock, say traders.
Jubilant Life Sciences is up 7%, has received approvals for Mycophenolate Mofetil, an immuno-suppressant, and Rizatriptan from US FDA
— Rajalakshmi Nirmal (@crajalakshmic)
January 6, 2015At 10.30 am, the stock was up Rs 10.60 or 7.59 per cent at Rs 150.30 on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.